Evidence map›Paper›PMID 25845499›Full record

ArticleExperimental cell research2015

Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.

Michael A Sheard, Matthew V Ghent, Daniel J Cabral, Joanne C Lee, Vazgen Khankaldyyan, Lingyun Ji, Samuel Q Wu, Min H Kang, Richard Sposto, Shahab Asgharzadeh and 1 more

Open access · greenAbstract read
In one paragraph

Article in Experimental cell research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Michael A SheardDevelopmental Therapeutics Program, USC-CHLA Institute for Pediatric Clinical Research, Division of Hematology-Oncology, Children׳s Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027, USA. Electronic address: msheard@chla.usc.edu.
Matthew V GhentDepartment of Pathology, Keck School of Medicine, University of Southern California, Health Sciences Campus, Los Angeles, CA 90089, USA. Electronic address: mattghent@gmail.com.
Daniel J CabralCancer Center and Departments of Cell Biology & Biochemistry, Pharmacology & Neuroscience, Internal Medicine and Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. Electronic address: dcabral14@gmail.com.
Joanne C LeeCancer Center and Departments of Cell Biology & Biochemistry, Pharmacology & Neuroscience, Internal Medicine and Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. Electronic address: joannebarnhart@gmail.com.
Vazgen KhankaldyyanDevelopmental Therapeutics Program, USC-CHLA Institute for Pediatric Clinical Research, Division of Hematology-Oncology, Children׳s Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027, USA. Electronic address: khangaldian@yahoo.com.
Lingyun JiDevelopmental Therapeutics Program, USC-CHLA Institute for Pediatric Clinical Research, Division of Hematology-Oncology, Children׳s Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027, USA. Electronic address: lingyun.ji@med.usc.edu.
Samuel Q WuMedical Genetics, Children׳s Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027, USA. Electronic address: swu@chla.usc.edu.
Min H KangCancer Center and Departments of Cell Biology & Biochemistry, Pharmacology & Neuroscience, Internal Medicine and Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. Electronic address: min.kang@ttuhsc.edu.
Richard SpostoDevelopmental Therapeutics Program, USC-CHLA Institute for Pediatric Clinical Research, Division of Hematology-Oncology, Children׳s Hospital Los Angeles, 4650 Sunset Blvd., Los Angeles, CA 90027, USA. Electronic address: rsposto@chla.usc.edu.
Shahab AsgharzadehDepartment of Pediatrics, Keck School of Medicine, University of Southern California, Health Sciences Campus, Los Angeles, CA 90089, USA. Electronic address: sasgharzadeh@chla.usc.edu.
C Patrick ReynoldsCancer Center and Departments of Cell Biology & Biochemistry, Pharmacology & Neuroscience, Internal Medicine and Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. Electronic address: patrick.reynolds@ttuhsc.edu.
Children's Hospital of Los Angeles · USTexas Tech University · USUniversity of Southern California · USTexas Tech University Health Sciences Center · US

Funding

Altered Glycolytic Pathway in in vitro Models of leukemia developed in hypoxiaR15CA159308 · NCI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI KANG, MIN HEE · 2011 to 2011
$444k
NCI NIH HHS R15 CA159308
6 · The paper itself

Abstract

Cancer cells typically exhibit increased glycolysis and decreased mitochondrial oxidative phosphorylation, and they continue to exhibit some elevation in glycolysis even under aerobic conditions. However, it is unclear whether cancer cell lines employ a high level of glycolysis comparable to that of the original cancers from which they were derived, even if their culture conditions are changed to physiologically relevant oxygen concentrations. From three childhood acute lymphoblastic leukemia (ALL) patients we established three new pairs of cell lines in both atmospheric (20%) and physiologic (bone marrow level, 5%) oxygen concentrations. Cell lines established in 20% oxygen exhibited lower proliferation, survival, expression of glycolysis genes, glucose consumption, and lactate production. Interestingly, the effects of oxygen concentration used during cell line initiation were only partially reversible when established cell cultures were switched from one oxygen concentration to another for eight weeks. These observations indicate that ALL cell lines established at atmospheric oxygen concentration can exhibit relatively low levels of glycolysis and these levels are semi-permanent, suggesting that physiologic oxygen concentrations may be needed from the time of cell line initiation to preserve the high level of glycolysis commonly exhibited by leukemias in vivo.

Indexed as

Cell Culture TechniquesGlycolysisPhenotypeAnimalsCell Line, TumorColorimetryGene Expression ProfilingGlucoseHumansMaleMiceMice, Inbred NODMice, SCIDOxygenPrecursor Cell Lymphoblastic Leukemia-LymphomaReal-Time Polymerase Chain ReactionGlucoseOxygenGlycolysisOxygenProliferation

Identifiers

PMID25845499
PMCPMC8219348
OpenAlexW2007239150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.